Biogen Launches Phase III ALS Trial

Biogen and Knopp Biosciences have begun enrolling patients in a Phase III clinical trial of their ALS drug, dexpramipexole. The trial aims to enroll about 800 participants and will take place over the course of approximately one year. The drug has received Fast Track and Orphan statuses from the US FDA.

Click here to read more.

Share this: